BSX BOSTON SCIENTIFIC CORP
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 885725 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.9%
TTM net income YoY25.1%
TTM EPS YoY26.7%
Revenue 3-yr CAGR15.3%
Net income 3-yr CAGR41.8%
Margins
Gross margin69.1%
Operating margin18.7%
Net margin16.6%
FCF margin15.8%
EBITDA margin25.5%
Returns
ROE14.3%
ROA7.9%
ROIC (approx.)10.6%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets43.1%
Debt / equity0.47x
Current ratio1.36x
Interest coverage10.46x
Cash quality & payout
Operating cash flow / net income1.21x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue4.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B |
| Cost of revenue | $6.22B | $5.26B | $4.34B | $3.96B | $3.71B |
| Gross profit | $13.85B | $11.49B | $9.90B | $8.73B | $8.18B |
| R&D expense | $2.05B | $1.61B | $1.41B | $1.32B | $1.20B |
| SG&A expense | $6.89B | $5.98B | $5.19B | $4.52B | $4.36B |
| Operating income | $3.61B | $2.60B | $2.34B | $1.65B | $1.20B |
| Interest expense | $349.00M | $305.00M | $265.00M | $470.00M | $341.00M |
| Pretax income | $3.38B | $2.28B | $1.99B | $1.14B | $1.08B |
| Income tax | $493.00M | $436.00M | $393.00M | $443.00M | $36.00M |
| Net income | $2.90B | $1.85B | $1.59B | $698.00M | $1.04B |
| EBITDA | $4.98B | $3.87B | $3.54B | $2.79B | $2.29B |
| EPS (basic) | 1.96 | 1.26 | 1.08 | 0.45 | 0.69 |
| EPS (diluted) | 1.94 | 1.25 | 1.07 | 0.45 | 0.69 |
| Weighted avg. shares (diluted) | 1.49B | 1.49B | 1.46B | 1.44B | 1.43B |
| Balance sheet | |||||
| Cash & equivalents | $1.97B | $606.00M | $865.00M | $1.13B | $2.17B |
| Inventory | $2.94B | $2.81B | $2.48B | $1.87B | $1.61B |
| Current assets | $8.79B | $6.92B | $6.51B | $5.76B | $6.32B |
| PP&E, net | $4.04B | $3.29B | $2.86B | $2.45B | $2.25B |
| Goodwill | $18.28B | $17.09B | $14.39B | $12.92B | $11.99B |
| Intangibles | $7.02B | $6.68B | $6.00B | $5.90B | $6.12B |
| Total assets | $43.67B | $39.40B | $35.14B | $32.47B | $32.23B |
| Current liabilities | $5.44B | $6.40B | $4.93B | $3.80B | $4.27B |
| Short-term debt | $299.00M | $1.78B | $531.00M | $20.00M | $261.00M |
| Long-term debt | $11.14B | $8.97B | $8.57B | $8.91B | $8.80B |
| Total debt | $11.44B | $10.75B | $9.10B | $8.94B | $9.06B |
| Total liabilities | $19.20B | $17.39B | $15.61B | $14.90B | $15.61B |
| Shareholders' equity | $24.23B | $21.77B | $19.28B | $17.57B | $16.62B |
| Net debt | $9.47B | $10.14B | $8.24B | $7.81B | $6.90B |
| Cash flow statement | |||||
| Operating cash flow | $4.53B | $3.44B | $2.50B | $1.53B | $1.87B |
| Capital expenditure | $876.00M | $790.00M | $711.00M | $588.00M | $554.00M |
| Free cash flow | $3.66B | $2.65B | $1.79B | $938.00M | $1.32B |
| Investing cash flow | -$2.64B | -$5.69B | -$2.57B | -$2.01B | -$1.60B |
| Financing cash flow | -$395.00M | $1.81B | $5.00M | -$548.00M | -$95.00M |
| Depreciation & amortization | $1.37B | $1.27B | $1.20B | $1.14B | $1.09B |
| Stock-based compensation | $299.00M | $266.00M | $233.00M | $220.00M | $194.00M |
| Dividends paid | — | $0 | $28.00M | $55.00M | $55.00M |
| Share buybacks | — | — | — | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.